Clinical Trials Have a Technology Problem. The Technology Problem Has an Engineering Problem
Clinovera | First Line Software | August 2026
Somewhere in the gap between a promising pilot and a production deployment, most clinical trial AI projects stall. Not because the model failed. Not because the data wasn’t there. Because nobody had made a decision about who owned the system once it shipped.
That’s the pattern, at least in our experience. Organisations invest months building something that works well enough in controlled conditions, then discover that production is a different environment entirely — different data distributions, different edge cases, different regulatory questions. And there’s no governance loop catching any of it.
The research reflects this. Only 15% of enterprise AI pilots successfully transition to full production scale (Productboard, 2026). The clinical trials context makes this more consequential than most: every day a Phase III trial runs behind costs a sponsor $55,716 (Tufts CSDD, 2024). A 12-month reduction in development timelines adds more than $400 million in net present value (McKinsey, 2025). The engineering failure isn’t academic.
The failure is structural
Clinical trials fail for reasons that have little to do with science. More than 80% fail to meet their original enrollment timelines (Tufts CSDD). Nearly half of all investigative sites either enroll nobody or fall short of targets. Up to 32.5% of Phase III data collected per patient is non-core — it ends up in the Clinical Study Report but doesn’t drive any primary endpoint (TransCelerate + Tufts CSDD, 2025). Sponsors are paying to collect data they don’t need, from sites that aren’t enrolling, running timelines they’re almost guaranteed to miss.
AI can help with all of this. Site selection algorithms that improve identification of top-enrolling sites by 30 to 50%. Document generation tools that cut CSR drafting time from 12 weeks to 6. Protocol design support that surfaces non-core data collection before the study starts, not after. These aren’t hypothetical capabilities — they’re deployed and producing results.
What’s harder is building them in a way that survives contact with a regulated production environment.
What “AI for clinical trials” actually requires
The clinical research context has specific engineering constraints that general-purpose AI deployments don’t face. HIPAA governs how patient data is processed and stored. The FDA’s AI/ML guidance framework governs how AI-enabled systems are positioned for regulatory submissions. The EU AI Act (fully in effect August 2026) classifies healthcare AI in its high-risk category, with requirements for transparency, human oversight, and audit trails. GCP principles apply to data provenance.
None of this is insurmountable. But it does mean that the engineering architecture matters from day one, not as a compliance afterthought.
The data interoperability layer is a specific technical challenge. Clinical research data lives in EHR systems built by different vendors, running different versions of different standards, with varying interpretations of what “FHIR-compliant” actually means in practice. Mapping patient data from different hospital formats into a common model like OMOP/CDM is a genuine engineering problem that requires clinical domain expertise alongside software expertise. Getting it wrong produces data quality issues that propagate through every downstream analysis.
FHIR adoption in outpatient settings has reached 64% (2024 State of FHIR Survey) — which sounds like progress until you realise it means more than a third of clinical sites still aren’t using it, and many that are use implementations that don’t interoperate cleanly. The gap between the standard and the reality is where most integration projects run into trouble.
The specification problem
Here’s the piece most organisations underestimate. When AI systems execute on a task — extracting structured information from referral documents, scoring sites for enrollment potential, generating first drafts of regulatory submissions — the quality of the output is bounded by the quality of the specification.
Imprecise requirements produce AI systems that work most of the time. “Most of the time” in a clinical context is different from “most of the time” in a consumer application. An AI-driven patient admission system that misclassifies 3% of cases isn’t a rounding error — it’s a patient safety and reimbursement issue. The spec needs to be precise enough that the acceptable error rate, the edge cases, and the human override conditions are all defined before the build starts, not discovered during testing.
This is a different engineering discipline than traditional software delivery. It requires people who understand both the clinical workflow and the AI failure modes — and a delivery structure that surfaces specification gaps early rather than late.
What actually closes the gap
There are four things that consistently differentiate clinical trial AI deployments that reach production and stay there from those that stall or quietly get switched off.
Ownership, defined before the first line of code. Every AI system in a clinical context needs a named owner — not the vendor, not “the technology team.” One person who gets paged when output quality degrades, who signs off on model updates, who runs the eval suite before each release. The question “who owns this agent?” needs an answer on day one.
Open standards, sponsor-controlled infrastructure. Patient data that flows through third-party platforms creates HIPAA exposure, GDPR questions, and dependency on vendor pricing decisions over the life of the research programme. Systems built on FHIR, OMOP/CDM, and HL7 — running in the sponsor’s own cloud or on-premise environment — give sponsors data sovereignty and the flexibility to extend or migrate as needs change.
A pre-production evaluation gate that runs every release. A shared eval suite — representative prompts, expected output ranges, automated acceptance tests, human sign-off for anything patient-facing — catches regressions before users do. This needs to be mandatory and non-negotiable, not a best-practice aspiration.
Post-launch drift monitoring. Models update. Input distributions shift as trials mature. What performed well in study start-up can degrade in month eight of data collection. A lightweight governance loop — output sampling, drift alerts, regular review cadence — turns AI system maintenance from a reactive scramble into a managed process.
Where the field is heading
Gartner’s Hype Cycle for Life Science R&D (2025) places the transition from document-based to data-first clinical workflows at the Peak of Inflated Expectations — meaning organisations are beginning to invest seriously and early results are visible, even though full production outcomes are still ahead of most deployments. That’s typically where the engineering partners who can actually deliver gain ground on vendors still promising.
McKinsey’s 2025 analysis of agentic AI in biopharma development is striking in how operational it has become: database build timelines down from two to three months to under two weeks, regulatory review time reduced by up to 40 days, statistical programming productivity up 60%. These are engineering achievements, not model capabilities. The model is the commodity. The engineering around it — the governance, the integration, the evaluation frameworks — is where the value is.
The global AI-in-clinical-trials market is valued at $2.4 billion in 2025, projected to reach $6.5 billion by 2030 (BCC Research). Generative AI alone could generate $60 to $110 billion in annual economic value for pharma and medical product companies (McKinsey Global Institute, 2024).
The organisations that will capture most of that value are the ones building now — with the right engineering foundations, the right governance, and partners who have delivered clinical AI in production before.
About Clinovera
Clinovera is the healthcare AI engineering practice of First Line Software — 500+ engineers, Anthropic Select Partner, delivering AI systems in production across pharmaceutical, life sciences, and clinical research organisations. Clinovera builds on open standards — FHIR, OMOP/CDM, HL7 — with HIPAA and GDPR compliance built in, using RACE Programming to deliver working systems in one week.
